The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
Open accessAbstract
Neuropsychiatric systemic lupus erythematosus (NPSLE) is a generic definition referring to a series of neurological and psychiatric symptoms directly related to systemic lupus erythematosus (SLE). NPSLE includes heterogeneous and rare neuropsychiatric (NP) manifestations involving both the central and peripheral nervous system. Due to the lack of a gold standard, the attribution of NP symptoms to SLE represents a clinical challenge that obligates the strict exclusion of any other potential cause. In the acute setting, management of these patients does not differ from other non-SLE subjects presenting with the same NP manifestation. Afterwards, an individualized therapeutic strategy, depending on the presenting manifestation and severity of symptoms, must be started. Clinical trials in NPSLE are scarce and most of the data are extracted from case series and case reports. High-dose glucocorticoids and intravenous cyclophosphamide remain the cornerstone for patients with severe symptoms that are thought to reflect inflammation or an underlying autoimmune process. Rituximab, intravenous immunoglobulins, or plasmapheresis may be used if response is not achieved. When patients present with mild to moderate NP manifestations, or when maintenance therapy is warranted, azathioprine and mycophenolate may be considered. When symptoms are thought to reflect a thrombotic underlying process, anticoagulation and antiplatelet agents are the mainstay of therapy, especially if antiphospholipid antibodies or antiphospholipid syndrome are present. Recent trials on SLE using new biologicals, based on newly understood SLE mechanisms, have shown promising results. Based on what we currently know about its pathogenesis, it is tempting to speculate how these new therapies may affect the management of NPSLE patients. This article provides a comprehensive and critical review of the literature on the epidemiology, pathophysiology, diagnosis, and management of NPSLE. We describe the most common pharmacological treatments used in NPSLE, based on both a literature search and our expert opinion. The extent to which new drugs in the advanced development of SLE, or the blockade of new targets, may impact future treatment of NPSLE will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280 · cited 1×
“Loss-of-function mutations in TREX1 have been shown to augment production of type I IFNs in mice and also in a patient with early-onset cerebral NPSLE [29, 30].”
BackgroundRuiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919 · cited 1×
“The rate of minor hemorrhagic complications was slightly increased in patients treated with high-intensity anticoagulation [167, 168].”
BackgroundBertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070367 · Cited by 762 · cited 2×
“Nowadays, azathioprine (2–3 mg/kg/day) is mainly used in SLE patients presenting with arthritis, mucocutaneous manifestations, and serositis, and as maintenance therapy in lupus nephritis [57].”
BackgroundFINAZZI, G., MARCHIOLI, R., BRANCACCIO, V., SCHINCO, P., WISLOFF, F., MUSIAL, J., BAUDO, F., BERRETTINI, M., Testa, S., D'ANGELO, A., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01340.x · Cited by 585
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Mechanisms of action of mycophenolate mofetil
Allison, A. (2005) · Lupus · doi:10.1177/096120330501400102 · Cited by 480
Antiphospholipid Antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke
(2004) · JAMA · doi:10.1001/jama.291.5.576 · Cited by 478 · cited 1×
“A study focusing on arterial cerebral events showed similar rates of recurrent thrombotic events over 2 years and risk of major bleeding in patients treated with low-dose aspirin or warfarin therapy [166].”
BackgroundTWEAK induces liver progenitor cell proliferation
Jakubowski, A., Ambrose, C., Parr, M., Lincecum, J. M., Wang, M. Z., Zheng, T. S., Browning, B., Michaelson, J. S., Baestcher, M., Wang, B., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23486 · Cited by 419
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
Ruiz‐Irastorza, G., Hunt, B. J., & Khamashta, M. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23109 · Cited by 324
Jung, H., Bobba, R., Su, J., Shariati‐Sarabi, Z., Gladman, D. D., Urowitz, M., Lou, W., & Fortin, P. R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27289 · Cited by 291 · cited 1×
“the risk of all thrombovascular events in SLE [64].”
BackgroundLosing your nerves? Maybe it's the antibodies
Diamond, B., Huerta, P. T., Mina-Osorio, P., Kowal, C., & Volpe, B. T. (2009) · Nature Reviews Immunology · doi:10.1038/nri2529 · Cited by 247
Petri, M. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0141-y · Cited by 206
Depression and Cognitive Impairment in Newly Diagnosed Systemic Lupus Erythematosus
PETRI, M., NAQIBUDDIN, M., CARSON, K. A., WALLACE, D. J., WEISMAN, M. H., HOLLIDAY, S. L., SAMPEDRO, M., PADILLA, P. A., & BREY, R. L. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.091366 · Cited by 117 · cited 1×
“patients with depression and cognitive dysfunction may benefit from antidepressants [49].”
Background
Cited by
Systemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
Frankovich, J., Swedo, S., Murphy, T., Dale, R. C., Agalliu, D., Williams, K., Daines, M., Hornig, M., Chugani, H., Sanger, T., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0148 · Cited by 139
Metadata
- Authors
- Magro-Checa, C., Zirkzee, E. J., Huizinga, T. W., & Steup-Beekman, G. M.
- Venue
- Drugs
- Published
- 2016-01-26
- Volume
- 76
- Issue
- 4
- Pages
- 459-483
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2289235163
- Cited by
- 235
- References
- 20
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.